A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02851095
Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 112
- Registration Number
- NCT02846532
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT02846519
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02846506
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Biological: PlaceboBiological: Golimumab
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT02846545
Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 102
- Registration Number
- NCT02841150
A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT02837692
Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT02833831
A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications
Completed
- Conditions
- StrokeMyocardial InfarctionHemorrhage, GastrointestinalKidney Diseases
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 144337
- Registration Number
- NCT02830178
A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Neoplasms
- Interventions
- Drug: JNJ-64457107
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 95
- Registration Number
- NCT02829099
© Copyright 2025. All Rights Reserved by MedPath